IMUGENE LIMITED — Board/Management Information 2015

Jun 4, 2015

==> picture [161 x 72] intentionally omitted <==

Leading European Immunologist Prof Ursula Wiedermann Appointed Imugene Chief Scientific Officer

Melbourne, Australia, 5th June 2015: Imugene Limited (ASX: IMU), a clinical stage immunooncology company, has appointed University Prof Dr Ursula Wiedermann as Chief Scientific Officer (CSO) of the company.

Prof Dr Wiedermann has worked as the Principal Investigator for the preclinical development of HER-Vaxx alongside Professor Christophe Zielinski, and currently serves on the Company’s scientific advisory board. Together they performed the Phase I Clinical trial of HER-Vaxx in metastatic breast cancer patients.

Prof Dr Wiedermann is the Professor of Vaccinology at the Medical University of Vienna, one of the oldest and largest medical campuses in Europe. She has a distinguished scientific career with a particular interest in immunology and vaccines, has over 110 publications in peer reviewed scientific journals to her credit and is a frequent speaker at international conferences.

Imugene Managing Director Charles Walker said, “This is a real coup for Imugene and we are delighted to have a scientist of such international renown as Prof Dr Wiedermann formalise her position in the Company as CSO. Ursula is a founding inventor of HER-Vaxx and her resume reflects her extraordinary prowess as a scientist, physician and educator and confirms her status as one of the leading lights in immuno-oncology globally. The CSO appointment is part of our ongoing initiative to put in place a first class management team capable of realizing the very significant opportunity that is our HER-Vaxx technology. Ursula will be visiting Australia in July and the company will arrange a number of presentations giving investors the opportunity to meet with Ursula. Investors will be notified nearer the time.”

Commenting on the appointment Prof Dr Wiedermann said, “Since my first introduction to Imugene several years ago I have strongly supported the HER-Vaxx development strategy and believe both our interests are aligned in bringing this exciting cancer technology to market as soon as possible. As the coinventor of the science and my new closer role in the company we can surely develop HER-Vaxx in a shorter time-frame.”

About Imugene:

Imugene (ASX; IMU) is a clinical stage immuno-oncology company developing HER-2+ gastric and breast cancer immunotherapies. The Company’s lead product is HER-Vaxx, a proprietary HER-2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase 1 study in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.

Charles Walker	Paul Hopper (Los Angeles)
Managing Director	Executive Chairman
Tel: +61 (0) 4 5044 6990	Tel: +1 858 334 5820 (US)
cwalker[at]imugene.com	Tel: +61 406 671 515 (Australia)
www.imugene.com	receptogen[at]earthlink.net
Media contact:	Stephanie Carrington (NYC)
Rudi Michelson	Integrated Corporate Relations (ICR)
Monsoon Communications	Ph: 646-277-1282
+61 3 9620 3333	stephanie.carrington@icrinc.com
rudim[at]monsoon.com.au

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com